KeyCorp Issues Positive Forecast for ICU Medical (NASDAQ:ICUI) Stock Price

ICU Medical (NASDAQ:ICUI) had its price objective upped by KeyCorp from $187.00 to $189.00 in a report published on Friday,Benzinga reports. They currently have an overweight rating on the medical instruments supplier’s stock.

A number of other analysts have also recently commented on the stock. BTIG Research upped their price objective on shares of ICU Medical from $170.00 to $200.00 and gave the company a “buy” rating in a research report on Friday, August 7th. Weiss Ratings upgraded shares of ICU Medical from a “hold (c-)” rating to a “hold (c)” rating in a report on Thursday, October 8th. Wall Street Zen raised shares of ICU Medical from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 8th. Raymond James Financial reaffirmed a “strong-buy” rating and issued a $200.00 target price on shares of ICU Medical in a research note on Friday, August 7th. Finally, Needham & Company LLC increased their target price on ICU Medical from $165.00 to $187.00 and gave the stock a “buy” rating in a report on Friday, August 7th. Two equities research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $195.20.

ICU Medical Trading Up 2.7%

Shares of ICUI stock traded up $4.46 during trading hours on Friday, reaching $172.11. The company had a trading volume of 464,850 shares, compared to its average volume of 219,459. ICU Medical has a 1-year low of $113.37 and a 1-year high of $192.85. The company has a debt-to-equity ratio of 0.56, a current ratio of 2.43 and a quick ratio of 1.21. The firm has a market cap of $4.30 billion, a price-to-earnings ratio of 72.01, a P/E/G ratio of 2.04 and a beta of 0.88. The company has a 50 day moving average of $162.91 and a 200 day moving average of $149.27.

ICU Medical (NASDAQ:ICUI) last announced its quarterly earnings data on Thursday, November 5th. The medical instruments supplier reported $2.44 EPS for the quarter, topping analysts’ consensus estimates of $2.14 by $0.30. The business had revenue of $556.22 million during the quarter, compared to analysts’ expectations of $552.03 million. ICU Medical had a return on equity of 7.91% and a net margin of 1.39%. The firm’s quarterly revenue was up 4.4% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.03 earnings per share. On average, equities research analysts anticipate that ICU Medical will post 7.22 EPS for the current year.

Insiders Place Their Bets

In other ICU Medical news, VP Virginia Sanzone sold 4,856 shares of ICU Medical stock in a transaction on Thursday, September 3rd. The shares were sold at an average price of $168.69, for a total transaction of $819,158.64. Following the completion of the transaction, the vice president directly owned 14,604 shares of the company’s stock, valued at $2,463,548.76. The trade was a 24.95% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Christian Voigtlander sold 8,929 shares of ICU Medical stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $182.93, for a total transaction of $1,633,381.97. Following the transaction, the chief operating officer directly owned 37,377 shares of the company’s stock, valued at approximately $6,837,374.61. This trade represents a 19.28% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 21,830 shares of company stock worth $3,905,003 in the last three months. Insiders own 2.10% of the company’s stock.

Institutional Trading of ICU Medical

A number of hedge funds have recently modified their holdings of the stock. Allworth Financial LP bought a new stake in shares of ICU Medical during the 2nd quarter worth about $26,000. Versant Capital Management Inc grew its position in shares of ICU Medical by 26.2% in the third quarter. Versant Capital Management Inc now owns 313 shares of the medical instruments supplier’s stock valued at $50,000 after purchasing an additional 65 shares during the last quarter. Public Employees Retirement System of Ohio bought a new position in shares of ICU Medical during the second quarter worth approximately $51,000. Rockefeller Capital Management L.P. increased its stake in shares of ICU Medical by 21.6% during the fourth quarter. Rockefeller Capital Management L.P. now owns 823 shares of the medical instruments supplier’s stock worth $117,000 after purchasing an additional 146 shares during the period. Finally, Nykredit A S acquired a new stake in ICU Medical during the 2nd quarter worth approximately $135,000. Institutional investors and hedge funds own 96.10% of the company’s stock.

Key ICU Medical News

Here are the key news stories impacting ICU Medical this week:

• Positive Sentiment: Q3 results exceeded expectations: ICU Medical reported earnings of $2.44 per share versus the $2.14 consensus estimate, while revenue of $556.22 million also topped forecasts. Revenue rose 4.4% year over year, and earnings increased from $2.03 per share a year earlier. Zacks Q3 earnings report
• Positive Sentiment: Full-year outlook remains solid: The company reaffirmed its 2026 guidance and expects results at the high end of its forecast range, supporting confidence in its near-term performance. Q3 results and guidance
• Positive Sentiment: Analyst targets moved higher: Piper Sandler raised its target to $200 and maintained an Overweight rating; KeyCorp lifted its target to $189 and also kept an Overweight rating. BTIG reiterated its Buy rating and $200 target. These endorsements signal continued analyst confidence in potential upside. BTIG rating update
• Neutral Sentiment: Management will present at the Jefferies Global Healthcare Conference in London on November 15–18. The appearance may provide an opportunity to discuss the business, but no new financial information was announced. Conference announcement

ICU Medical Company Profile

ICU Medical, Inc develops, manufactures and sells medical devices and systems used in infusion therapy, critical care and oncology. Its products are designed to support the delivery of fluids, medications and nutrition while helping healthcare providers improve safety and efficiency in clinical settings.

The company’s portfolio includes infusion pumps, dedicated and non-dedicated administration sets, needle-free connectors, intravenous solutions and other infusion consumables. ICU Medical also offers products for critical care monitoring and vascular access, as well as closed-system transfer devices and related technologies used in the preparation and administration of hazardous drugs.

Founded in 1984, ICU Medical has expanded through internal development and acquisitions, including the acquisition of Hospira’s infusion systems business in 2017 and Smiths Medical in 2022.